{"id":4911,"date":"2025-10-17T12:01:22","date_gmt":"2025-10-17T02:01:22","guid":{"rendered":"\/eu-uk\/?p=4911"},"modified":"2025-10-17T12:01:22","modified_gmt":"2025-10-17T02:01:22","slug":"30-0-million-placement-to-accelerate-global-commercialisation-and-advance-product-portfolio","status":"publish","type":"post","link":"\/eu-uk\/blog\/2025\/10\/17\/30-0-million-placement-to-accelerate-global-commercialisation-and-advance-product-portfolio\/","title":{"rendered":"$30.0 Million Placement to Accelerate Global Commercialisation and Advance Product Portfolio"},"content":{"rendered":"<p><span data-contrast=\"auto\">Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">The capital raising received strong international and domestic demand from institutional and sophisticated investors, resulting in the addition of several US institutions to the share register. Canaccord Genuity acted as Sole Lead Manager to the Placement.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Proceeds from the raising will be used to:<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<ul>\n<li><span data-contrast=\"auto\">accelerate the US roll out of the Company\u2019s flagship nerve repair product Remplir\u2122<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">undertake clinical studies to commercialise the use of Remplir in the significant prostate cancer surgery market<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">advance commercialisation of pipeline products in tendon and ligament repair\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">expand capacity at Orthocell\u2019s existing manufacturing facility<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">invest in new applications and technologies in the regenerative medicine sector.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<p data-ccp-border-between=\"0px none #000000\" data-ccp-padding-between=\"0px\"><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:120,&quot;335559740&quot;:276,&quot;335572071&quot;:0,&quot;335572072&quot;:0,&quot;335572073&quot;:4278190080,&quot;335572075&quot;:0,&quot;335572076&quot;:0,&quot;335572077&quot;:4278190080,&quot;335572079&quot;:0,&quot;335572080&quot;:0,&quot;335572081&quot;:4278190080,&quot;335572083&quot;:0,&quot;335572084&quot;:0,&quot;335572085&quot;:4278190080,&quot;335572087&quot;:0,&quot;335572088&quot;:0,&quot;335572089&quot;:4278190080,&quot;469789798&quot;:&quot;none&quot;,&quot;469789802&quot;:&quot;none&quot;,&quot;469789806&quot;:&quot;none&quot;,&quot;469789810&quot;:&quot;none&quot;,&quot;469789814&quot;:&quot;none&quot;}\">\u00a0<\/span><span data-contrast=\"auto\">Orthocell CEO and MD, Paul Anderson, said:\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{}\">\u00a0<\/span><i><span data-contrast=\"auto\">\u201cWe have built significant momentum in the commercialisaiton of Remplir and the funds from the capital raising will be focused on accelerating that process.\u00a0 We greatly appreciate the support we have received from new and existing institutional and high net worth investors and particularly welcome our new investors from the US.\u00a0 We see that as a significant endorsement of our strategy and progress to date as well as the near-term revenue that can be generated from the US market.\u201d<\/span><\/i><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/cdn-api.markitdigital.com\/apiman-gateway\/ASX\/asx-research\/1.0\/file\/2924-03009501-6A1290876&amp;v=undefined\"><span data-ccp-props=\"{}\">\u00a0<\/span><b><span data-contrast=\"auto\">Click to read the ASX release<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement.  <\/p>\n","protected":false},"author":2,"featured_media":4912,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4911","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4911"}],"version-history":[{"count":2,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4911\/revisions"}],"predecessor-version":[{"id":4914,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4911\/revisions\/4914"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4912"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4911"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}